OSE Immunotherapeutics SA announced that at its Combined General Shareholders' Meeting held on June 22, 2023. They approved the appointment of Eric Leire as a new independent Director and of Anne-Laure Autret-Cornet, Chief Financial Officer, as Director representing the employee shareholders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.75 EUR | -3.57% | +8.87% | +57.71% |
04-17 | OSE: licensing agreement with AbbVie enters into force | CF |
04-17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.71% | 157M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- OSE Stock
- News OSE Immunotherapeutics
- OSE Immunotherapeutics SA Appoints Eric Leire as A New Independent Director and Anne-Laure Autret-Cornet as Director